Metabolomics Analysis of the Development of Sepsis and Potential Biomarkers of Sepsis-Induced Acute Kidney Injury

Table 4

Differential metabolic pathways (CT vs. LPS2 vs. LPS6). The results of enriched compounds after screening and metabolic pathway enrichment analysis (MPEA) (CT vs. LPS2 vs. LPS6) are summarized in this table.

	Total in pathway	Expected	Hits	Raw P		Holm P	FDR	Impact	Enriched compounds
Pantothenate and CoA biosynthesis	15	0.52425	4	0.001355	6.6038	0.10977	0.10864	0.15384	Beta-alanine; L-Cysteine; Pantothenic acid; Uracil
Biosynthesis of unsaturated fatty acids	42	1.4679	6	0.002682	5.9211	0.21459	0.10864	0	(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Arachidonic acid; Linoleic acid; Oleic acid; Palmitic acid; Stearic acid
Aminoacyl-tRNA biosynthesis	67	2.3417	7	0.007184	4.936	0.5675	0.19395	0.14581	L-Alanine; L-Arginine; L-Cysteine; L-Histidine; L-Methionine; L-Proline; L-Tryptophan
Glyoxylate and dicarboxylate metabolism	16	0.5592	3	0.016309	4.116	1	0.33026	0.16666	Glyceric acid; Glycolic acid; Isocitric acid
Taurine and hypotaurine metabolism	8	0.2796	2	0.029294	3.5304	1	0.40633	0.5	L-Cysteine; Taurine
Citrate cycle (TCA cycle)	20	0.699	3	0.030099	3.5033	1	0.40633	0.13794	Fumaric acid; Isocitric acid; Pyruvic acid
Alanine, aspartate, and glutamate metabolism	24	0.8388	3	0.048471	3.0268	1	0.56088	0.04	Fumaric acid; L-Alanine; Pyruvic acid

Holm: Holm-Bonferroni method; FDR: false discovery rate.